PLEASANTON, Calif., July 23, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data across more than 100 countries with Veeva OpenData and Veeva Network. Accurate and comprehensive customer reference data from OpenData will equip Boehringer Ingelheim's teams with the insights needed to engage healthcare professionals (HCPs) with relevant information, while laying the data foundation to scale AI."Extending our trusted p ...

WALTHAM, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the SPEAR (Spike Protein Elimination and Recovery) Study Group. The SPEAR Study Group was launched earlier this month to focus on the biology and clinical disease or injury associated with persistent presence of spike antigen from SARS-CoV-2 virus or COVID-19 vaccines. Dr. Iwasaki is internationally recognized for her ...

Core Insights - Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, with a pipeline that includes seven programs, three of which are in clinical stages [1][3] - The company will host a conference call and live webcast on August 6, 2025, to report its second quarter 2025 financial results and provide a business update [1][2] Company Overview - Neumora's mission is to address the global brain disease crisis by innovating the development of treatments for neuropsychiatric disorders and neurodegenerative diseases [3] - The therapeutic pipeline targets novel mechanisms of action and is supported by a suite of translational, clinical, and computational tools aimed at enabling precision medicine [3]

Core Insights - ANI Pharmaceuticals, Inc. announced results from the NEW DAY clinical trial evaluating ILUVIEN for diabetic macular edema (DME) [1][2] - The trial compared the mean number of supplemental aflibercept injections needed in patients treated with ILUVIEN versus those treated with aflibercept [2][3] - The primary endpoint was not met, but secondary endpoints showed a significant reduction in time to first supplemental injection for the ILUVIEN arm [2][4] Study Design and Results - The NEW DAY trial was a multicenter, randomized, active-controlled study involving 306 eyes of treatment-naïve DME patients [8] - Patients were randomized to receive either a single ILUVIEN injection or five monthly aflibercept injections, followed by supplemental injections as needed [2][8] - In the intent-to-treat population, the ILUVIEN arm had a mean of 2.4 supplemental injections compared to 2.5 in the aflibercept arm, which was not statistically significant (p=0.756) [2] - In a post-hoc analysis, the ILUVIEN arm showed a statistically significant reduction in supplemental injections (1.8 vs. 2.5, p=0.029) [3] Secondary Endpoints - The mean time from the last treatment injection to the first supplemental injection was significantly longer in the ILUVIEN arm (185.4 days) compared to the aflibercept arm (132.8 days, p<0.001) [2] - Visual acuity changes showed non-inferiority between the two arms, with a mean change of 1.8 letters in the ILUVIEN arm versus 5.5 letters in the aflibercept arm (p=0.080) [5] - Central subfield thickness changes were also similar, with ILUVIEN showing a mean change of -118.8 µm compared to -113.6 µm for aflibercept (p=0.709) [6] Safety Profile - ILUVIEN was well tolerated, with 41% of patients experiencing treatment-related adverse events, primarily cataracts and increased intraocular pressure [7] - Serious treatment-related adverse events were not reported in either arm [7] - The incidence of intraocular pressure increase was higher in the ILUVIEN arm (16%) compared to the aflibercept arm (3%) [7] Implications for Treatment - The results suggest that ILUVIEN may reduce the treatment burden for patients with DME, potentially supporting its earlier use in clinical practice [4][7] - The study highlights the multifactorial nature of DME and the need for effective treatment options [4]

CHENGDU, China, July 23, 2025 /PRNewswire/ -- BGM Group (the "Company" or "BGM") (NASDAQ: BGM) today announced that it will release its unaudited financial results for the first half 2025 before the U.S. financial markets open on July 24, 2025 Eastern Daylight Time.About BGM BGM Group Ltd. has a strategic focus on the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals.In terms of AI application implementation, the group relies on adv ...

Compounds developed through collaboration with Variational AI show targeted activityVANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced meaningful progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (Ataxia Telangiectasia and Rad3-rel ...

Core Insights - Ipsen announced changes to its Executive Committee, effective September 1, 2025, with Mari Scheiffele, Andreas Gerber, and Caroline Sitbon taking on new roles [1][5][7] Group 1: Executive Appointments - Mari Scheiffele will transition from leading commercial operations in the International Region to overseeing all medicines in Oncology and Rare Disease, focusing on product development and pipeline innovation [2][5] - Andreas Gerber joins Ipsen from Johnson & Johnson as Head of International, responsible for operations outside North America, leveraging his experience in Oncology to drive growth in Ipsen's therapeutic areas [3][5] - Caroline Sitbon has been promoted to General Counsel, leading legal and business ethics, and will also serve as the General Secretary of the Board of Directors [4][5] Group 2: Leadership Perspectives - CEO David Loew expressed confidence in the new appointments, highlighting the combination of internal promotions and new leadership as a strength for Ipsen's ongoing transformation [5] - Mari Scheiffele emphasized her commitment to innovation and excellence in her new role [5] - Andreas Gerber expressed enthusiasm for leading the International Region and making a positive impact on patients' lives [5] - Caroline Sitbon conveyed her excitement about ensuring compliance and integrity within the organization [5] Group 3: Company Overview - Ipsen is a global biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease, and Neuroscience, with nearly 100 years of development experience [6][8] - The company operates in over 40 countries and provides medicines to patients in more than 80 countries [8]

Core Viewpoint - Pharvaris N.V. has announced the pricing of an underwritten offering of 8,250,000 ordinary shares at $20.00 per share and pre-funded warrants to purchase 500,000 ordinary shares at $19.99 each, aiming to raise approximately $175 million before expenses [1]. Group 1: Offering Details - The offering includes 8,250,000 ordinary shares priced at $20.00 each and pre-funded warrants for 500,000 shares at $19.99 each, with the total gross proceeds expected to be around $175 million [1]. - Pharvaris has granted underwriters a 30-day option to purchase an additional 1,312,500 ordinary shares at the public offering price [1]. - The offering is expected to close on or about July 24, 2025, subject to customary closing conditions [1]. Group 2: Company Background - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases, including hereditary angioedema (HAE) [5]. - The company aims to provide injectable-like efficacy and placebo-like tolerability with the convenience of oral therapies for preventing and treating angioedema attacks [5]. - Pharvaris is currently conducting pivotal Phase 3 studies for the prevention and on-demand treatment of HAE attacks [5]. Group 3: Underwriters - Morgan Stanley, Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot Kempen are acting as joint book-running managers for the offering [2]. - The shares and pre-funded warrants are being offered under an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission [2].

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to pre ...

DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss 2025 second quarter financial results and provide a business and financial update.Interested parties may register for the call in advance here or via the Investors section of the Jazz Pha ...